Cervical Cancer Clinical Trial
Official title:
Randomized Trial to Increase Adherence to Cervical Cancer Screening Guidelines for Young Women
The goal of this study is to prevent over screening and over treatment of young women for cervical precancers, which can result in psychological distress and has been associated with future risk of premature deliveries. Current national guidelines recommend that routine screening be performed at less-frequent intervals and that excisional cervical therapies are discouraged in young women. The objectives of this study are to examine physician- and patient-based interventions designed to decrease over screening and over treatment by increasing adherence to US guidelines for women under 30 years.
In this study, we compare two different intervention arms that are designed to prevent over
screening and over treatment by increasing adherence to the new US cervical cancer screening
guidelines and the American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines
for the management of abnormal cervical cancer screening tests and cancer precursors.
Specifically, the interventions will focus on the newly recommended cervical cancer screening
intervals and decreasing the number of colposcopy procedures and cervical procedures for
abnormal cytology.
This is a cluster randomized trial with individual clinics serving as the clusters. Clinics
from the California Family PACT provider network who serve at least 200 female clients per
year under 30 years of age will be randomized to one of two arms: 1) ASCCP mobile application
(ProvAPP)-based intervention for providers, or 2) ProvAPP + Patient education Tool (Tab)
intervention. These groups will be compared to a control comparison group of 28 clinics
chosen using propensity score matching based on clinic characteristics such as county and
private versus public from the Family PACT claims data. The ProvAPP intervention is for
clinicians' mobile phones and will help them maneuver through current guidelines based on
patient age and condition. An existing application from the ASCCP will be updated to include
screening guidelines and to be more user-friendly. The patient-based Tab intervention will be
a patient education tool accessible via URL on a tablet device at the time of check-in to
assist in asking questions and evaluating treatment options. The tool will be developed with
input from women age 21-29 as well as other stakeholders including Latinas Contra Cancer and
the National Cervical Cancer Coalition. It is hypothesized that the ProvAPP+Tab approach will
be most successful; all interventions will be more successful than no intervention.
Family PACT serves predominantly uninsured women and 40% of clients are Latina. We plan to
enroll 7 sites (ProvAPP) and 7 sites (ProvAPP+Tab) into the other intervention arm with an
average of 2,800 women to 3,500 women aged 21-29 years per arm (14 sites) with a similar
number of sites and women randomly chosen for the comparison arm (28 sites) resulting in a
total of 39 sites and 8,400-10,500 women. We will use Family PACT claims data to examine, by
age, the number of and average interval between cytology specimens, colposcopy examinations,
and the number of excisional procedures.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |